Free Trial

Kavar Capital Partners Group LLC Trims Holdings in Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson logo with Medical background

Kavar Capital Partners Group LLC cut its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 8.1% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 46,788 shares of the company's stock after selling 4,136 shares during the period. Johnson & Johnson comprises approximately 1.1% of Kavar Capital Partners Group LLC's portfolio, making the stock its 26th largest position. Kavar Capital Partners Group LLC's holdings in Johnson & Johnson were worth $6,766,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Powers Advisory Group LLC lifted its position in Johnson & Johnson by 0.6% during the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the company's stock valued at $1,538,000 after acquiring an additional 61 shares during the last quarter. Eagle Wealth Strategies LLC lifted its position in Johnson & Johnson by 2.8% during the third quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company's stock valued at $372,000 after acquiring an additional 63 shares during the last quarter. Knuff & Co LLC lifted its position in Johnson & Johnson by 0.7% during the third quarter. Knuff & Co LLC now owns 9,466 shares of the company's stock valued at $1,534,000 after acquiring an additional 64 shares during the last quarter. Perkins Coie Trust Co raised its holdings in shares of Johnson & Johnson by 1.8% in the third quarter. Perkins Coie Trust Co now owns 3,705 shares of the company's stock worth $600,000 after buying an additional 65 shares during the last quarter. Finally, Vertex Planning Partners LLC raised its holdings in shares of Johnson & Johnson by 1.3% in the third quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company's stock worth $844,000 after buying an additional 65 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

JNJ traded down $0.33 on Monday, reaching $151.82. 6,679,844 shares of the company's stock were exchanged, compared to its average volume of 9,497,993. The stock has a market cap of $365.53 billion, a PE ratio of 22.83, a P/E/G ratio of 2.44 and a beta of 0.52. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The stock's fifty day moving average price is $147.61 and its 200-day moving average price is $156.12. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period in the previous year, the business posted $2.29 earnings per share. Johnson & Johnson's quarterly revenue was up 5.3% on a year-over-year basis. Sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.27%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio (DPR) is presently 74.59%.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company's stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on JNJ. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Thursday, January 23rd. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Barclays raised their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a report on Tuesday, January 28th. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Finally, Raymond James reduced their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and an average price target of $170.67.

Check Out Our Latest Report on Johnson & Johnson

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Recommended Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Archer Aviation: Sinking Now, Soaring Soon?

Archer Aviation: Sinking Now, Soaring Soon?

MarketBeat analyst Gabriel Osario-Mazilli breaks down what’s next for Archer and how investors should play this move.

Related Videos

NVIDIA Revenue SOARS 78%, But Volatility Won’t STOP!
These Are the 3 Stocks Most Likely to SPLIT in 2025
NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines